Published in Urol Int on November 13, 2010
Genome-wide association study identifies a second prostate cancer susceptibility variant at 8q24. Nat Genet (2007) 19.18
Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA (2005) 8.72
Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. Cancer Res (2009) 7.11
Common sequence variants on 2p15 and Xp11.22 confer susceptibility to prostate cancer. Nat Genet (2008) 6.10
Germline mutations in HOXB13 and prostate-cancer risk. N Engl J Med (2012) 5.49
Active surveillance program for prostate cancer: an update of the Johns Hopkins experience. J Clin Oncol (2011) 5.27
Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy. JAMA (2008) 5.25
Two genome-wide association studies of aggressive prostate cancer implicate putative prostate tumor suppressor gene DAB2IP. J Natl Cancer Inst (2007) 4.85
Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. J Urol (2003) 4.66
Association between two unlinked loci at 8q24 and prostate cancer risk among European Americans. J Natl Cancer Inst (2007) 4.24
African American men with very low-risk prostate cancer exhibit adverse oncologic outcomes after radical prostatectomy: should active surveillance still be an option for them? J Clin Oncol (2013) 4.20
Prostate-specific antigen kinetics during follow-up are an unreliable trigger for intervention in a prostate cancer surveillance program. J Clin Oncol (2010) 4.17
Predicting 15-year prostate cancer specific mortality after radical prostatectomy. J Urol (2011) 3.36
Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism: a randomized controlled trial. JAMA (2006) 3.32
Obesity-related plasma hemodilution and PSA concentration among men with prostate cancer. JAMA (2007) 3.25
An evaluation of the decreasing incidence of positive surgical margins in a large retropubic prostatectomy series. J Urol (2004) 3.21
Evidence for two independent prostate cancer risk-associated loci in the HNF1B gene at 17q12. Nat Genet (2008) 3.14
Delay of surgery in men with low risk prostate cancer. J Urol (2011) 3.05
Factors associated with satisfaction with prostate cancer care: results from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE). BJU Int (2012) 2.88
Death in patients with recurrent prostate cancer after radical prostatectomy: prostate-specific antigen doubling time subgroups and their associated contributions to all-cause mortality. J Clin Oncol (2007) 2.79
An updated prostate cancer staging nomogram (Partin tables) based on cases from 2006 to 2011. BJU Int (2012) 2.77
Germline mutations and sequence variants of the macrophage scavenger receptor 1 gene are associated with prostate cancer risk. Nat Genet (2002) 2.76
Increased intra-abdominal fat predicts perioperative complications following minimally invasive partial nephrectomy. Urology (2013) 2.70
Prognostic Gleason grade grouping: data based on the modified Gleason scoring system. BJU Int (2013) 2.69
The natural history of metastatic progression in men with prostate-specific antigen recurrence after radical prostatectomy: long-term follow-up. BJU Int (2011) 2.68
Retracted EPCA-2: a highly specific serum marker for prostate cancer. Urology (2007) 2.67
Pathological outcomes in men with low risk and very low risk prostate cancer: implications on the practice of active surveillance. J Urol (2013) 2.66
PCA3: a molecular urine assay for predicting prostate biopsy outcome. J Urol (2008) 2.63
Characteristics of insignificant clinical T1c prostate tumors. A contemporary analysis. Cancer (2004) 2.61
Prediction of mortality after radical prostatectomy by Charlson comorbidity index. Urology (2010) 2.54
Outcomes of radical cystectomy for transitional cell carcinoma of the bladder: a contemporary series from the Bladder Cancer Research Consortium. J Urol (2006) 2.51
Optimizing bladder cancer locoregional failure risk stratification after radical cystectomy using SWOG 8710. Cancer (2014) 2.48
Prostate cancer gene 3 (PCA3): development and internal validation of a novel biopsy nomogram. Eur Urol (2009) 2.45
A prospective, multicenter, National Cancer Institute Early Detection Research Network study of [-2]proPSA: improving prostate cancer detection and correlating with cancer aggressiveness. Cancer Epidemiol Biomarkers Prev (2010) 2.36
PTEN protein loss by immunostaining: analytic validation and prognostic indicator for a high risk surgical cohort of prostate cancer patients. Clin Cancer Res (2011) 2.35
The Melbourne Consensus Statement on the early detection of prostate cancer. BJU Int (2014) 2.32
National trends in the utilization of partial nephrectomy before and after the establishment of AUA guidelines for the management of renal masses. Urology (2013) 2.28
Long-term survival after radical prostatectomy for men with high Gleason sum in pathologic specimen. Urology (2010) 2.27
A delay in radical cystectomy of >3 months is not associated with a worse clinical outcome. BJU Int (2007) 2.25
Comparative analysis of minimally invasive partial nephrectomy techniques in the treatment of localized renal tumors. Urology (2012) 2.22
Prostate cancer imaging trends after a nationwide effort to discourage inappropriate prostate cancer imaging. J Natl Cancer Inst (2013) 2.20
ICUD-EAU International Consultation on Bladder Cancer 2012: Radical cystectomy and bladder preservation for muscle-invasive urothelial carcinoma of the bladder. Eur Urol (2012) 2.19
Metabolic factors associated with benign prostatic hyperplasia. J Clin Endocrinol Metab (2006) 2.17
Accuracy of PCA3 measurement in predicting short-term biopsy progression in an active surveillance program. J Urol (2009) 2.17
Lymphovascular invasion is independently associated with overall survival, cause-specific survival, and local and distant recurrence in patients with negative lymph nodes at radical cystectomy. J Clin Oncol (2005) 2.13
Pathological upstaging during radical cystectomy is associated with worse recurrence-free survival in patients with bacillus Calmette-Guerin-refractory bladder cancer. Urology (2009) 2.10
Corporal "snake" maneuver: corporoglanular shunt surgical modification for ischemic priapism. J Sex Med (2009) 2.07
A thorough pelvic lymph node dissection in presence of positive margins associated with better clinical outcomes in radical cystectomy patients. Urology (2009) 2.06
External validation of University of California, San Francisco, Cancer of the Prostate Risk Assessment score. Urology (2008) 2.04
Smoking knowledge assessment and cessation trends in patients with bladder cancer presenting to a tertiary referral center. Urology (2011) 2.04
Is ultrasound imaging inferior to computed tomography or magnetic resonance imaging in evaluating renal mass size? Urology (2012) 2.03
Outcomes of a bladder cancer screening program using home hematuria testing and molecular markers. Eur Urol (2013) 2.01
Impact of surgical delay on long-term cancer control for clinically localized prostate cancer. J Urol (2004) 1.95
Individual and cumulative effect of prostate cancer risk-associated variants on clinicopathologic variables in 5,895 prostate cancer patients. Prostate (2009) 1.95
Advanced age is associated with poorer bladder cancer-specific survival in patients treated with radical cystectomy. Eur Urol (2006) 1.86
Discrepancy between clinical and pathologic stage: impact on prognosis after radical cystectomy. Eur Urol (2006) 1.82
Initial prostate biopsy: development and internal validation of a biopsy-specific nomogram based on the prostate cancer antigen 3 assay. Eur Urol (2012) 1.81
Association of [-2]proPSA with biopsy reclassification during active surveillance for prostate cancer. J Urol (2012) 1.80
Graft reconstruction of inferior vena cava for renal cell carcinoma stage pT3b or greater. Urology (2011) 1.80
Gleason score 6 adenocarcinoma: should it be labeled as cancer? J Clin Oncol (2012) 1.78
Tertiary Gleason patterns and biochemical recurrence after prostatectomy: proposal for a modified Gleason scoring system. J Urol (2009) 1.77
Adjuvant weekly docetaxel for patients with high risk prostate cancer after radical prostatectomy: a multi-institutional pilot study. J Urol (2007) 1.75
Clinical epidemiology of nonurothelial bladder cancer: analysis of the Netherlands Cancer Registry. J Urol (2010) 1.74
Association of prostate cancer risk variants with clinicopathologic characteristics of the disease. Clin Cancer Res (2008) 1.74
Prognostic significance of Gleason score discrepancies between needle biopsy and radical prostatectomy. Eur Urol (2007) 1.72
Phase II, randomized, placebo-controlled trial of neoadjuvant celecoxib in men with clinically localized prostate cancer: evaluation of drug-specific biomarkers. J Clin Oncol (2009) 1.71
ProPSA and diagnostic biopsy tissue DNA content combination improves accuracy to predict need for prostate cancer treatment among men enrolled in an active surveillance program. Urology (2011) 1.71
Repeat prostate biopsy and the incremental risk of clinically insignificant prostate cancer. Urology (2011) 1.70
Lymphoepithelioma-like carcinoma of the urinary tract: a clinicopathological study of 30 pure and mixed cases. Mod Pathol (2007) 1.67
The increasing use of intravesical therapies for stage T1 bladder cancer coincides with decreasing survival after cystectomy. BJU Int (2007) 1.65
Correlation between serum prostate-specific antigen and cancer volume in prostate glands of different sizes. Urology (2010) 1.64
Validation of the partin nomogram for prostate cancer in a national sample. J Urol (2010) 1.64
Regional variation in total cost per radical prostatectomy in the healthcare cost and utilization project nationwide inpatient sample database. J Urol (2010) 1.64
Residual tumor potentially left behind after local ablation therapy in prostate adenocarcinoma. J Urol (2008) 1.63
Increased incidence of pathologically nonorgan confined prostate cancer in African-American men eligible for active surveillance. Urology (2013) 1.63
Long-term cancer control of radical prostatectomy in men younger than 50 years of age: update 2003. Urology (2003) 1.62
Prostate specific antigen testing among the elderly--when to stop? J Urol (2009) 1.62
Treatment outcomes of radical prostatectomy in potential candidates for 3 published active surveillance protocols. Urology (2009) 1.62
Causes of death after radical prostatectomy at a large tertiary center. J Urol (2012) 1.61
Under diagnosis and over diagnosis of prostate cancer. J Urol (2007) 1.61
A novel risk stratification to predict local-regional failures in urothelial carcinoma of the bladder after radical cystectomy. Int J Radiat Oncol Biol Phys (2012) 1.61
Prognostic risk stratification and clinical outcomes in patients undergoing surgical treatment for renal cell carcinoma with vascular tumor thrombus. Urology (2007) 1.60
Nuclear roundness variance predicts prostate cancer progression, metastasis, and death: A prospective evaluation with up to 25 years of follow-up after radical prostatectomy. Prostate (2010) 1.60
Clinical outcomes following radical cystectomy for primary nontransitional cell carcinoma of the bladder compared to transitional cell carcinoma of the bladder. J Urol (2006) 1.60
Geometric evaluation of systematic transrectal ultrasound guided prostate biopsy. J Urol (2012) 1.59
Radical prostatectomy in older men: survival outcomes in septuagenarians and octogenarians. BJU Int (2010) 1.58
Disparities in treatment and outcome for renal cell cancer among older black and white patients. J Clin Oncol (2007) 1.56
Substratification of stage T1C prostate cancer based on the probability of biochemical recurrence. Urology (2002) 1.56
Initial experience with laparoscopic transvesical ureteral reimplantation at the Children's Hospital of Philadelphia. J Urol (2006) 1.55
Multiparametric magnetic resonance imaging findings in men with low-risk prostate cancer followed using active surveillance. BJU Int (2013) 1.55
Corporal Burnett "Snake" surgical maneuver for the treatment of ischemic priapism: long-term followup. J Urol (2012) 1.54